Dr Reddy's April-June quarter earnings have surpassed street estimates with net profit rising 14 percent to Rs 626 crore from Rs 550.4 crore in corresponding quarter last fiscal. Total income, - See more at: http://ways2capital-review.blogspot.in/2015/07/dr-reddys-q1-beats-street-net-rises-14.html#sthash.88GdPtaK.dpuf
The S&P BSE Sensex started on a cautious note on Wednesday following muted trend seen in other Asian markets. The fall in the index was led by losses in Dr Reddy's Laboratories, HDFC, Bharti Airtel, and ICICI Bank. Get Expert Advice for Stock and Commodity Market Trading www.marketmagnify.com/stock-cash-tips.php
Shares of Dr Reddy's Laboratories added 1.3 percent intraday Monday after the drug maker launched HAiROOTZ. - See more at: http://ways2capital.blogspot.in/2015/06/dr-reddys-labs-climbs-on-hair-growth.html#sthash.CGEFA6hN.dpuf
INDIAN EQUITY MARKET OUTLOOK -7 June, 2017 : Major Headlines of the day: • Reliance Communications- Moody’s revises rating to Ca from Caa1, Fitch revises rating to RD from CCC • Yes Bank-Shareholders approve increase in borrowing limit to Rs 70,000 crore from Rs 50,000 crore and fundraising up to Rs 20,000 crore via non-convertible debentures (NCDs) • Adani Enterprises-Stake in Adani Green Energy diluted to below 50 percent and Adani Green ceases to be a unit of Adani Enterprises
Hyderabad-based company, Dr Reddy's Laboratories, declared here nowadays that it's launched over-the-counter (OTC) Fexofenadine coordination compound and alkaloid coordination compound in North American nation market increasing their power to sixty and one hundred twenty mg severally.